New Device Measures Effects of Cannabis on the Brain
Zentrela, a Canadian AI neurotechnology company has declared the launch of its brainwave analysis device in Europe.
The Cognalyzer® is a transportable non-invasive machine that scans the EEG (brainwaves) of cannabis consumers and uses AI to measure if someone is under the psychoactive effects of cannabis.
Originally launched in Canada and the US in 2021 after five years of research and development and with independent scientific validation, the appliance strives to provide a quicker, cost-effective way to perform accurate, reliable research into the effects of cannabis. It offers an exciting alternative to lengthy and expensive clinical trials.
The Cognalyzer® is launching at a point when countries are increasingly reforming to more liberal policies around the consumption of cannabis, with Germany moving towards semi-legalisation in April of this year. With the emergence of the cannabis market in the EU, there is now a need more urgent than ever for reliable and accurate information on the effects of cannabis that will allow Europeans to make informed decisions about consumption and purchases.
What Does this Mean For Cannabis Research?
For the last three years, companies such as PAX and Kinloch Wellness, are reported to have been incorporating the device in observational and controlled investigations to try and accurately calculate the psychoactive consequences of cannabis products.
“This is the real disruptive value of our proprietary AI and wearable EEG technology. We’ve created a new way of conducting human trials for cannabis effect research that can be completed in three months rather than 18-month studies, including clinical trials." - Zentrela Press Release
What Else Can This Device be Used?
The value of this new device and the possibilities it presents are seemingly endless. European cannabis businesses, research universities, labs, clinics and even police forces will now be able to incorporate the wearable EEG device into their research models.
The range of valuable research applications includes the device and technology being possibly used to explore further the topic of cannabis-impaired driving.
The device may also be valuable in the examination of the cannabinoids and their immediate relationship to factors like BMI or gender. It may also help support medical professionals in prescribing cannabis medicines at doses which minimise undesirable side effects.
Zentrela also intends to expand its scope beyond measuring the psychoactive effects of cannabis and look to calculate which pharmaceutical treatments used in the treatment of anxiety and depression are most effective for individuals. This is as well as monitoring brain biomarkers like relaxation and stress accurately.
More From Soft Secrets:
Stoners Aren't Lazy Says New Research
L
Liz Filmer
